Immunovant Inc reports results for the quarter ended December 31 - Earnings Summary

Immunovant

10/02/2025 14:31

* Immunovant Inc  IMVT.OQ  reported a quarterly adjusted
loss
of 76 cents​​ per share for the quarter ended December 31, lower
than the same quarter last year, when the company reported EPS
of -36 cents.  The mean expectation of twelve analysts for the
quarter was for a loss of 75 cents per share. Wall Street
expected results to range from -83 cents to -53 cents per share.
    * Reported revenue was zero​; analysts expected zero. 
    * Immunovant Inc's reported EPS for the quarter was a loss
of 76
cents​.
    * The company reported a quarterly loss of $111.12 million.
    * Immunovant Inc shares had fallen by 17.6% this quarter.

FORECAST CHANGES
    * The mean earnings estimate of analysts had fallen by
about 1.4%
in the last three months.​ 
    * In the last 30 days, one analyst negatively revised an
earnings
estimate

RECOMMENDATIONS
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 13 "strong buy" or "buy," 1
"hold" and no "sell" or "strong sell." 
    * The average consensus recommendation for the biotechnology
&
medical research peer group is also "buy"

Wall Street's median 12-month price target for Immunovant Inc is
$51.00 
This summary was machine generated from LSEG data February 10 at
02:31 p.m. UTC. ​All figures in US dollars unless otherwise
stated. (For questions concerning the data in this report,
contact Estimates.Support@lseg.com. For any other questions or
feedback, contact RefinitivNewsSupport@thomsonreuters.com) QUARTER ENDING    ESTIMATE       ACTUAL         BEAT, MET,
                                                 MISSED
 Dec. 31 2024      -0.75          -0.76          Missed
 Sep. 30 2024      -0.60          -0.74          Missed
 Jun. 30 2024      -0.53          -0.60          Missed
 Mar. 31 2024      -0.43          -0.52          Missed